VIA
AERI

Vident Investment Advisory’s Aerie Pharmaceuticals AERI Stock Holding History

Vident Investment Advisory’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,304
Closed -$548K – 992
2018
Q1 		$548K Buy
+10,304
New +$576K 0.02% 576

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vident Investment Advisory's AERI Position: Q2 2018 in Review

Vident Investment Advisory sold out of Aerie Pharmaceuticals (AERI) in Q2 2018, closing a stake of 10,304 shares — an estimated $548K sold.

Vident Investment Advisory first reported a position in AERI in Q1 2018 and held it in 1 quarter. The position peaked at $548K in Q1 2018. 175 funds tracked by Wall St. Rank hold AERI as of Q2 2018.

  • Vident Investment Advisory reported no remaining Aerie Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Vident Investment Advisory sold 10,304 Aerie Pharmaceuticals shares in Q2 2018, an estimated $548K.
  • Vident Investment Advisory first reported a position in Aerie Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Vident Investment Advisory's Aerie Pharmaceuticals position peaked at $548K in Q1 2018.
  • 175 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2018.

Based on Vident Investment Advisory's 13F filing for Q2 2018, filed 14 Aug 2018.